Concord Biotech is currently trading at Rs. 1937.10, up by 39.80 points or 2.10% from its previous closing of Rs. 1897.30 on the BSE.
The scrip opened at Rs. 1892.00 and has touched a high and low of Rs. 1945.00 and Rs. 1869.05 respectively. So far 9208 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2658.00 on 20-Sep-2024 and a 52 week low of Rs. 1370.05 on 07-May-2025.\
Last one week high and low of the scrip stood at Rs. 1945.00 and Rs. 1835.05 respectively. The current market cap of the company is Rs. 20297.64 crore.
The promoters holding in the company stood at 44.08%, while Institutions and Non-Institutions held 17.95% and 37.96% respectively.
Concord Biotech has incorporated wholly owned subsidiary company namely ‘Concord Lifegen’. The newly incorporated entity belongs to Biopharmaceutical Industry. The wholly owned subsidiary company is incorporated to manage the marketing, sales, and distribution of pharmaceutical products. Its primary objectives include executing targeted sales strategies, ensuring regulatory compliance across domestic and international markets, handling logistics and customer support, and maintaining transparent reporting to the holding company.
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: